The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.

It is a hallucinogenic drug, and is a controlled substance designed for use as an aesthetics. It also has now been touted for ...

Grand Junction City Council approved regulations for natural medicine facilities, which include the supervised use of magic mushrooms for health purposes last week.

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

A large study of 30,000 adults diagnosed with ADHD in the U.K. found women with ADHD died roughly nine years younger than women without a diagnosis. Men had about a seven-year shorter lifespan.

The UK injectable drug delivery market is set to grow at 8.80% CAGR through 2034, driven by rising obesity rates and the approval of weight-loss injectable.

Serenity Mental Health Centers is changing lives one patient at a time. Are you struggling with depression, anxiety, or PTSD? Serenity Mental Health ...

Impact of Disease questionnaire (PsAID-12) scores were associated with treatment escalation, physicians primarily relied on clinical assessments when making treatment decisions.